We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Smart Injectable Hydrogel with Oxygen-Scavenging Capability Inhibits Tumor Growth

By HospiMedica International staff writers
Posted on 06 Apr 2023

In recent decades, significant progress has been made in the development of different hypoxia-activated prodrugs (HAPs). More...

Despite this, the use of HAPs for cancer therapy continues to face obstacles such as suboptimal therapeutic results due to challenges in accessing the hypoxic area and the development of metastases due to hypoxia. Now, researchers have suggested a novel treatment approach that can enhance HAP-based chemotherapy and inhibit tumor metastasis.

In solid tumors, hypoxic areas with low oxygen levels are commonly found close to necrotic regions. These hypoxic zones are resistant to radiotherapy and chemotherapy, making them a target for selective therapy like HAPs. However, HAPs are ineffective in reaching hypoxic regions that are distant from the blood vessel network, leading to suboptimal exposure to HAPs and consequently low efficacy chemotherapy. A team of researchers at the Chinese Academy of Sciences (CAS, Beijing, China) has created a novel hypoxia-inducible chitosan polymer that can be combined with antiangiogenic Pazopanib to form an injectable hydrogel that is sensitive to oxygen.

The enzyme-mediated chemical reactions facilitate polymer reactions to oxygen, resulting in gelation. By utilizing this oxygen-depleting hydrogel in combination with HAPs, it is possible to enhance the hypoxic environment of tumors, which can lead to increased toxicity of HAPs for targeted chemotherapy. Additionally, when the hydrogel is exposed to high levels of ROS in tumor areas, responsive linkages within the hydrogel are broken, which leads to sustained release of Pazopanib and the inhibition of pulmonary metastasis.

“This novel hydrogel can significantly remodel tumor hypoxic microenvironment as a kind of engineered niche,” said Professor Shaoli Song, a co-supervisor the study. “We hope that our results will encourage scientists to continue investigating the use of HAP-based chemotherapy to combat cancer.”

Related Links:
Chinese Academy of Sciences 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.